Correlation between immunotherapy and intestinal flora evolution in non-small cell lung cancer

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053845

Enrollment

Unknown

Registered

2021-12-01

Start date

2021-12-06

Completion date

Unknown

Last updated

2022-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Control group:None

Bacillus group :Live bacillus licheniformis capsule

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Voluntarily participate in this research, fully understand and know this research and sign the informed consent; 2. Patients with primary non-small cell lung cancer with clear cytology or histological pathology; 3. Aged 18-80 (inclusive) years; 4. ECOG performance status score is 0-1; 5. Patients receiving immunotherapy.

Exclusion criteria

Exclusion criteria: 1. Patients with autoimmune diseases; 2. Patients with second primary tumor; 3. Patients who take laxatives, immunosuppressants, probiotics and other treatments for a long time; 4. Patients with digestive system diseases; 5. Patients who are positive for hepatitis B virus, hepatitis C virus, HIV and syphilis.

Design outcomes

Primary

Measure	Time frame
Overall survival;	—

Secondary

Measure	Time frame
Progression-free survival;Quality of life;	—

Countries

China

Contacts

Public ContactChen Jun

chenjundl@vip.sina.com+86 17709873616

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026